Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs

South West & Central
27 May 2014 09:28


Exclusive vacancies may not be shown here, please contact Daniel on +44 1494818040 or DanielB@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Daniel Birkitt-Smith
Recruitment Consultant
DanielB@zenopa.com
+44 1494818040

Testimonials
Thanks very much to the Zenopa team for all your help with finding me my great new position! You made my job search so easy by finding the vacancies, sending my CV.
Tom, 2011

Stryker completes Concentric Medical takeover

4 October 2011 00:00 in Medical Company Restructures


Stryker has announced the completion of its takeover of Concentric Medical, a leading developer of therapies for acute ischemic stroke.

Originally announced at the end of August 2011, the deal has seen Stryker pay $135 million (87.73 million pounds) to take control of Concentric, which is based in California and has been operating since 1999.

The newly-acquired firm is known for its offering of minimally invasive devices for the removal of thrombus in patients affected by stroke, such as the Trevo Retriever clot removal system, which is currently undergoing clinical trials.

Stryker expects the acquisition to expand its presence in the European, US and Japanese acute ischemic stroke markets, while giving it access to a workforce with proven expertise in this area.

The deal has also been forecast as having a neutral effect in the firm's earnings per share figure for 2011.

Stephen MacMillan, chairman, president and chief executive officer of Stryker, said: "We are further broadening our commitment to advancing care within the interventional neurovascular space by bringing innovative treatment options to the large and underserved ischemic stroke population."ADNFCR-8000103-ID-800747948-ADNFCR

Other news stories from 04/10/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd